Immunotherapy and Targeted Molecular Therapy in Thoracic Surgical Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 March 2025 | Viewed by 52
Special Issue Editors
Interests: lung cancer; esophageal cancer; circulating tumor cells; surgical education
Special Issue Information
Dear Colleagues,
Malignancies treated by thoracic surgeons include primary lung, esophageal, thymic, tracheal, and chest wall neoplasms. Many additional malignancies metastasize to the lungs, thoracic spine/ribs, and mediastinal lymph nodes. These cancers are varied in pathophysiology and tumor biology. Until recently, systemic treatment for locally advanced thoracic tumors was limited to chemotherapy, radiation, and palliative invasive interventions. This paradigm is being disrupted by the advent of targeted molecular therapy (TMT) and immunotherapy (IO). TMT utilizes small molecules to counteract tumor-specific gene alterations and altered cell biology. IO addresses alterations in the normal host immune response to cancer. Taken together, these medications have shown a documented efficacy in the palliative, adjuvant, and peri-operative settings, with ongoing investigations for expanded indications.
The purpose of this Special Issue is to (1) explore the foundational molecular/cell biology of TMT and IO; (2) provide an updated paradigm for the current use of TMT and IO in thoracic malignancies; (3) report ongoing efforts for expanded indications of TMT and IO in basic, translational, and clinical trial science; and (4) describe the future directions of TMT and IO clinical investigations. We welcome both original research and review articles.
Dr. Rishindra Mamidi Reddy
Dr. Ryan Albert John Campagna
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- lung cancer
- esophageal cancer
- targeted therapy
- thymic cancer
- adjuvant therapy
